United Phosphorous Ltd (UPL) is the largest producer in India of crop protection products with a range of products that include fumigants and fungicides among others. The company ranks amongst the top 5 post-patent agrochemical manufacturers in the w... More
Kanoria Chemicals & Industries (KCI) is a leading producer of chemical intermediates of Chloro (Chlorine) and Alco (Alcohol) in India. It has two production facilities, one at Renukoot in UP and the other at Ankleshwar, Gujarat. The UP facility is fu... More
UPL | KANORIA CHEMICALS | UPL / KANORIA CHEMICALS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 15.5 | -267.3 | - | View Chart |
P/BV | x | 2.7 | 0.4 | 633.1% | View Chart |
Dividend Yield | % | 1.1 | 1.3 | 81.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
UPL Mar-20 |
KANORIA CHEMICALS Mar-19 |
UPL / KANORIA CHEMICALS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,045 | 84 | 1,242.6% | |
Low | Rs | 240 | 55 | 438.5% | |
Sales per share (Unadj.) | Rs | 468.0 | 245.7 | 190.5% | |
Earnings per share (Unadj.) | Rs | 28.5 | -4.5 | -638.6% | |
Cash flow per share (Unadj.) | Rs | 47.9 | 6.9 | 697.7% | |
Dividends per share (Unadj.) | Rs | 6.00 | 0.75 | 800.0% | |
Dividend yield (eoy) | % | 0.9 | 1.1 | 86.5% | |
Book value per share (Unadj.) | Rs | 213.3 | 137.0 | 155.7% | |
Shares outstanding (eoy) | m | 764.05 | 43.69 | 1,748.8% | |
Bonus/Rights/Conversions | B | - | - | ||
Price / Sales ratio | x | 1.4 | 0.3 | 485.8% | |
Avg P/E ratio | x | 22.5 | -15.6 | -144.9% | |
P/CF ratio (eoy) | x | 13.4 | 10.1 | 132.6% | |
Price / Book Value ratio | x | 3.0 | 0.5 | 594.3% | |
Dividend payout | % | 21.0 | -16.8 | -125.3% | |
Avg Mkt Cap | Rs m | 491,017 | 3,034 | 16,182.4% | |
No. of employees | `000 | 4.7 | 0.4 | 1,339.9% | |
Total wages/salary | Rs m | 33,910 | 1,506 | 2,252.4% | |
Avg. sales/employee | Rs Th | 76,028.1 | 30,584.0 | 248.6% | |
Avg. wages/employee | Rs Th | 7,210.3 | 4,289.2 | 168.1% | |
Avg. net profit/employee | Rs Th | 4,631.1 | -555.6 | -833.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 357,560 | 10,735 | 3,330.8% | |
Other income | Rs m | 1,040 | 123 | 849.0% | |
Total revenues | Rs m | 358,600 | 10,858 | 3,302.8% | |
Gross profit | Rs m | 62,420 | 637 | 9,805.2% | |
Depreciation | Rs m | 14,810 | 495 | 2,992.5% | |
Interest | Rs m | 14,810 | 360 | 4,112.7% | |
Profit before tax | Rs m | 33,840 | -96 | -35,286.8% | |
Minority Interest | Rs m | 30 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -6,230 | -54 | 11,558.4% | |
Tax | Rs m | 5,860 | 45 | 12,961.7% | |
Profit after tax | Rs m | 21,780 | -195 | -11,168.7% | |
Gross profit margin | % | 17.5 | 5.9 | 294.4% | |
Effective tax rate | % | 17.3 | -47.1 | -36.7% | |
Net profit margin | % | 6.1 | -1.8 | -335.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 291,900 | 4,556 | 6,407.2% | |
Current liabilities | Rs m | 166,860 | 4,119 | 4,050.9% | |
Net working cap to sales | % | 35.0 | 4.1 | 859.6% | |
Current ratio | x | 1.7 | 1.1 | 158.2% | |
Inventory Days | Days | 80 | 65 | 123.8% | |
Debtors Days | Days | 121 | 50 | 244.5% | |
Net fixed assets | Rs m | 377,540 | 8,924 | 4,230.5% | |
Share capital | Rs m | 1,530 | 219 | 700.2% | |
"Free" reserves | Rs m | 161,430 | 5,767 | 2,799.4% | |
Net worth | Rs m | 162,960 | 5,985 | 2,722.8% | |
Long term debt | Rs m | 273,710 | 3,121 | 8,770.5% | |
Total assets | Rs m | 700,830 | 14,008 | 5,003.0% | |
Interest coverage | x | 3.3 | 0.7 | 447.7% | |
Debt to equity ratio | x | 1.7 | 0.5 | 322.1% | |
Sales to assets ratio | x | 0.5 | 0.8 | 66.6% | |
Return on assets | % | 5.2 | 1.2 | 443.0% | |
Return on equity | % | 13.4 | -3.3 | -410.2% | |
Return on capital | % | 9.7 | 2.3 | 420.9% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 43,547 | 135 | 32,348.2% | |
Fx outflow | Rs m | 29,555 | 350 | 8,451.4% | |
Net fx | Rs m | 13,992 | -215 | -6,505.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 87,390 | 215 | 40,608.7% | |
From Investments | Rs m | -26,430 | -859 | 3,077.9% | |
From Financial Activity | Rs m | -21,750 | 729 | -2,985.6% | |
Net Cashflow | Rs m | 38,980 | 85 | 45,858.8% |
Indian Promoters | % | 29.8 | 74.4 | 40.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 7.1 | 2.1 | 338.1% | |
FIIs | % | 48.6 | 0.0 | - | |
ADR/GDR | % | 0.1 | 0.0 | - | |
Free float | % | 14.5 | 23.4 | 62.0% | |
Shareholders | 82,466 | 11,560 | 713.4% | ||
Pledged promoter(s) holding | % | 8.3 | 0.0 | - |
Compare UPL With: CLARIANT CHEMICALS GUJARAT ALKALIES MONSANTO INDIA PHILLIPS CARBON BLACK BAYER CROP (I)
Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.
Here's an analysis of the annual report of UPL for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of UPL . Also includes updates on the valuation of UPL .
For the quarter ended December 2019, UPL has posted a net profit of Rs 8 bn (up 77.5% YoY). Sales on the other hand came in at Rs 89 bn (up 80.7% YoY). Read on for a complete analysis of UPL 's quarterly results.
For the quarter ended September 2019, UPL has posted a net profit of Rs 1 bn (down 60.9% YoY). Sales on the other hand came in at Rs 78 bn (up 83.6% YoY). Read on for a complete analysis of UPL 's quarterly results.
Here's an analysis of the annual report of UPL for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UPL . Also includes updates on the valuation of UPL .
Here's an analysis of the annual report of KANORIA CHEMICALS for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of KANORIA CHEMICALS. Also includes updates on the valuation of KANORIA CHEMICALS.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More